July 14, 2021 7:41am

The crystal ball has gone dark, indications are all but blank and the pick-up stock game is scattered

Pre-open indications: 1 SELL: GBT; 1 Maintain SELL: BSTG

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

Dow futures are UP +0.01% (+5 points), S&P futures are UP +0.09% (+4 point) and NASDAQ futures are UP +0.37% (+55 points)

 

U.S. stock index futures are drifting on Wednesday in the pre-open time-frame,

European stocks pulled back slightly as the pan-European Stoxx 600 slid 0.3% below the flatline in early trade,

Asia-Pacific stocks skidded following a hotter-than-expected U.S. inflation report released overnight.

 

Data Docket: Fed chief Powell delivers the semi-annual report to Congress on the state of the economy

 

Henry’omics:

Excellent quotes, Wharton School finance professor Jeremy Siegel said that rising inflation should not be seen as a reason to sell stocks. “Stocks are long-term excellent hedges against inflation,” Siegel said in an interview on “Halftime Report,” contrary to much of the conventional wisdom on Wall Street. “I think there’s going to be a lot more inflation,” added Siegel, a longtime market bull. But he added, “I’m not selling my stocks.”

Indexes continue to drift around their all-time highs.

 

Tuesday’s evening’s recap: “the ceiling collapsed taking sector share pricing plunging again with sentiment continually draining from the sector with low volume” … https://www.regmedinvestors.com/articles/11996

  • The Nasdaq closed DOWN – 55.59 points (-0.39);
  • The IBB closed down -0.98% and XBI closed down -1.67%
  • Sector volume was NADA with 0 of the 2-upside having higher than the 3-month average volume with NADA volume of 0 of 31-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was up +1.06 points or +6.25% at 17.18
  • Tuesday’s percentage (%) of the 2-upside were +1% (PGEN) to +9.99% (BSTG) while the 31-downside ranges from -0.27% (PSTI) to -9.04% (BLCM);

Q3/21: 3 positive and 5 negative close

Q2/21:

  • June: 15 positive and 8 negative closes
  • May:  8 positive, 12 negative closes and 1 holiday
  • April: 11 negative and 10 positive closes

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) Chronicles - Maintaining Sell – Could the share price stay up if it wasn’t being “pumped”?

Biostage (BSTG) closed up +$0.14 to $1.64 with 1,125 shares traded after Tuesday’s flat with 2,600 shares traded Monday’s $1.50 flat with 1,100 shares traded post Friday’s flat with 200 shares traded,

Question#1: Has Beijing, China “spoken” as yet another accounting firm has been retained? On July 6, 2021, BSTG’s Audit Committee engaged Wei, Wei & Co., LLP (with offices in Queens, New York, Los Angeles, California, and Beijing, China) to serve as the independent registered public accounting firm contingent upon completion of Wei’s client acceptance procedures - which will probably be waived by Beijing? Licensed to practice as certified public accountants in the states of New York, Connecticut, California, and New Jersey – what about Massachusetts?

Question#2: Is this also the third (3rd) accounting firm in five (5) years?

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.

 

The morning’s indications: sparse

Maintaining SELL:

Global Blood Therapeutics (GBT) closed down -$0.49 to $34.00 after Monday’s -$0.41 to $34.49 and Friday’s +$0.77 to $34.90 but, has a negative -$0.73 or -2.15% pre-market indication.

 

 

The BOTTOM LINE: Is this a session of “any which way” works … I also continue to MAINTAIN, this is a confused sector as sentiment rages and fades, momentum is usurped, fundamentals are being ignored.

 It takes courage to not being discouraged by “our” universe of cell and gene therapy equities or sector …

My focus has always been “indication and warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.

Q2 earnings LPS (loss-per-share) release date are being divulged

My motto, never leave an investor uninformed about what I know!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.